宏源药业
(301246)
| 流通市值：22.73亿 | | | 总市值：56.80亿 |
| 流通股本：1.60亿 | | | 总股本：4.00亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 480,717,282.91 | 437,835,714.18 | 745,590,069.83 | 1,021,446,462.93 |
| 交易性金融资产 | 1,388,930,095.17 | 1,183,066,289.74 | 900,317,511.65 | 665,095,065.07 |
| 应收票据及应收账款 | 547,314,523.89 | 547,529,463.73 | 526,540,762.91 | 496,964,335.2 |
| 其中：应收票据 | 255,635,103.91 | 267,563,892.63 | 290,116,454.87 | 234,699,831.41 |
| 应收账款 | 291,679,419.98 | 279,965,571.1 | 236,424,308.04 | 262,264,503.79 |
| 应收款项融资 | 94,761,894.39 | 76,543,147.11 | 32,903,555.03 | 53,151,904.6 |
| 预付款项 | 23,342,413.13 | 35,265,361.24 | 38,504,497.36 | 38,122,992 |
| 其他应收款合计 | 82,443,055.53 | 81,169,855.05 | 79,886,496.23 | 81,055,950.94 |
| 存货 | 296,384,114.25 | 288,108,965.26 | 270,528,377.11 | 238,623,488.82 |
| 其他流动资产 | 248,632,503.47 | 452,269,573.02 | 452,087,706.59 | 421,543,360.99 |
| 流动资产合计 | 3,162,525,882.74 | 3,101,788,369.33 | 3,046,358,976.71 | 3,016,003,560.55 |
| 非流动资产: | | | | |
| 长期股权投资 | 192,222,842.93 | 198,631,845.9 | 203,642,857.22 | 205,708,779.46 |
| 投资性房地产 | 3,894,846.42 | 3,915,824.05 | 3,936,801.68 | 3,957,779.31 |
| 固定资产 | 1,630,050,973.85 | 1,607,678,874.37 | 1,653,912,916.93 | 1,425,720,465.84 |
| 在建工程 | 648,576,615.03 | 668,912,164.01 | 630,574,445.25 | 876,608,341.92 |
| 使用权资产 | 7,220,066.09 | 7,462,842.48 | 7,705,618.87 | 6,783,744.35 |
| 无形资产 | 182,447,967.49 | 182,280,997.92 | 181,892,927.66 | 179,885,940.89 |
| 长期待摊费用 | 4,091,770.33 | 4,806,583.05 | 5,519,338.52 | 3,326,779.86 |
| 递延所得税资产 | 18,854,860.99 | 18,883,922.17 | 17,256,375.98 | 15,902,624.78 |
| 其他非流动资产 | 61,828,110.84 | 79,383,750.06 | 74,123,300.39 | 122,760,946.71 |
| 非流动资产合计 | 2,749,188,053.97 | 2,771,956,804.01 | 2,778,564,582.5 | 2,840,655,403.12 |
| 资产总计 | 5,911,713,936.71 | 5,873,745,173.34 | 5,824,923,559.21 | 5,856,658,963.67 |
| 流动负债: | | | | |
| 短期借款 | 160,673,984.22 | 168,060,167.58 | 59,317,883.35 | 55,401,696.72 |
| 应付票据及应付账款 | 675,672,722.55 | 756,146,484.3 | 777,271,649.26 | 841,896,769.5 |
| 其中：应付票据 | 336,858,255.54 | 375,706,836.69 | 344,279,217.59 | 352,476,784.89 |
| 应付账款 | 338,814,467.01 | 380,439,647.61 | 432,992,431.67 | 489,419,984.61 |
| 合同负债 | 12,718,620.05 | 18,217,745.22 | 13,874,566.32 | 21,867,225.52 |
| 应付职工薪酬 | 13,260,239.62 | 12,435,026.76 | 28,149,495.77 | 12,413,262.2 |
| 应交税费 | 5,753,905.77 | 11,177,890.39 | 6,816,710.65 | 4,054,649.2 |
| 其他应付款合计 | 46,357,569.35 | 41,166,957.71 | 33,927,264.77 | 46,211,687.8 |
| 一年内到期的非流动负债 | 90,477,587.81 | 77,974,607.48 | 77,746,048.77 | 68,928,604.98 |
| 其他流动负债 | 102,600,929.04 | 99,041,206.32 | 138,885,290.97 | 127,695,272.82 |
| 流动负债合计 | 1,107,515,558.41 | 1,184,220,085.76 | 1,135,988,909.86 | 1,178,469,168.74 |
| 非流动负债: | | | | |
| 长期借款 | 372,324,000 | 227,584,000 | 230,361,000 | 238,061,000 |
| 租赁负债 | 7,238,353.3 | 6,817,449.46 | 7,164,120.19 | 7,184,737.03 |
| 递延收益 | 72,243,642.98 | 75,414,253.16 | 68,641,367.33 | 64,619,904.51 |
| 递延所得税负债 | 21,724,271.59 | 22,143,449.07 | 21,621,624.62 | 21,462,569.93 |
| 非流动负债合计 | 473,530,267.87 | 331,959,151.69 | 327,788,112.14 | 331,328,211.47 |
| 负债合计 | 1,581,045,826.28 | 1,516,179,237.45 | 1,463,777,022 | 1,509,797,380.21 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 400,006,800 | 400,006,800 | 400,006,800 | 400,006,800 |
| 资本公积 | 2,172,677,544.98 | 2,172,614,891.5 | 2,172,316,086.47 | 2,172,141,087.07 |
| 减:库存股 | 47,149,748.2 | 47,149,748.2 | 32,795,729.27 | 31,405,166.14 |
| 专项储备 | 4,338,564.22 | 4,958,580.42 | 3,370,156.84 | 3,659,149.78 |
| 盈余公积 | 190,536,938.83 | 190,536,938.83 | 190,536,938.83 | 185,239,736.88 |
| 未分配利润 | 1,609,530,950.77 | 1,636,131,654.96 | 1,627,245,582.72 | 1,617,219,975.87 |
| 归属于母公司股东权益合计 | 4,329,941,050.6 | 4,357,099,117.51 | 4,360,679,835.59 | 4,346,861,583.46 |
| 少数股东权益 | 727,059.83 | 466,818.38 | 466,701.62 | - |
| 股东权益合计 | 4,330,668,110.43 | 4,357,565,935.89 | 4,361,146,537.21 | 4,346,861,583.46 |
| 负债和股东权益合计 | 5,911,713,936.71 | 5,873,745,173.34 | 5,824,923,559.21 | 5,856,658,963.67 |
| 公告日期 | 2025-08-28 | 2025-04-25 | 2025-04-25 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |